{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:59:51Z","timestamp":1793192391380,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["SCR_022380"],"award-info":[{"award-number":["SCR_022380"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016520"],"award-info":[{"award-number":["P30 CA016520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Dainippon Sumitomo Pharma America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001340","name":"W. W. Smith Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016255","name":"Inovio Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017119","name":"Wistar Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017119","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:10:49Z","timestamp":1779808249000},"page":"4778-4793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficient in vivo assembly of DNA encoded polyvalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Pratik S.","family":"Bhojnagarwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devivasha","family":"Bordoloi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tomirotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Frase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-8512","authenticated-orcid":false,"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.019_bib2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","article-title":"Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options","volume":"83","author":"Vikas","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.019_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/annonc\/mdi961","article-title":"consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41571-023-00803-9","article-title":"Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors","volume":"20","author":"Simpson","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.795547","article-title":"Immunotherapy in ovarian cancer: Thinking beyond PD-1\/PD-L1","volume":"11","author":"Chardin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in thetreatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ymthe.2026.05.019_bib8","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib13","article-title":"Generation of a half-life extended anti-CD19 BiTE\u00ae antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies","volume":"130","author":"Lorenczewski","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.019_bib14","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100046","article-title":"Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy","volume":"6","author":"Fuc\u00e0","year":"2021","journal-title":"ESMO open"},{"key":"10.1016\/j.ymthe.2026.05.019_bib16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14712598.2022.2095900","article-title":"The manufacturing considerations of bispecific antibodies","volume":"22","author":"Underwood","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"Knobs-into-holes engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ymthe.2026.05.019_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.019_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib20","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","article-title":"Blinatumomab, a Bispecific T-cell Engager (BiTE(\u00ae)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications","volume":"55","author":"Zhu","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2026.05.019_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.omto.2022.07.003","article-title":"In vivo DNA-launched bispecific T cell engager targeting IL-13R\u03b12 controls tumor growth in an animal model of glioblastoma multiforme","volume":"26","author":"Bhojnagarwala","year":"2022","journal-title":"Mol. Therapy-Onolytics"},{"key":"10.1016\/j.ymthe.2026.05.019_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126086","article-title":"DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.019_bib23","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.ymthe.2025.04.008","article-title":"DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets","volume":"33","author":"Bhojnagarwala","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40259-020-00412-3","article-title":"In vivo delivery of nucleic acid-encoded monoclonal antibodies","volume":"34","author":"Patel","year":"2020","journal-title":"Biodrugs"},{"key":"10.1016\/j.ymthe.2026.05.019_bib25","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1038\/s41591-025-03969-0","article-title":"Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial","volume":"31","author":"Tebas","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.019_bib26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-16-0492","article-title":"Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target","volume":"23","author":"Perales-Puchalt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162553","article-title":"A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy","volume":"7","author":"Bordoloi","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.05.019_bib30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ymthe.2019.03.005","article-title":"In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus","volume":"27","author":"Esquivel","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42090-5","article-title":"Enhanced antibody-antigen structure prediction from molecular docking using AlphaFold2","volume":"13","author":"Gaudreault","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.05.019_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4865","article-title":"Evaluation of AlphaFold antibody\u2013antigen modeling with implications for improving predictive accuracy","volume":"33","author":"Yin","year":"2024","journal-title":"Protein Sci."},{"key":"10.1016\/j.ymthe.2026.05.019_bib33","doi-asserted-by":"crossref","first-page":"e011073","DOI":"10.1136\/jitc-2024-011073","article-title":"Targeting IL13R\u03b12 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation","volume":"13","author":"Zhao","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather","year":"2018","journal-title":"elife"},{"key":"10.1016\/j.ymthe.2026.05.019_bib35","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.3390\/ijms21207496","article-title":"Toward drug-like multispecific antibodies by design","volume":"21","author":"Sawant","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.019_bib36","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.019_bib37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.biotechadv.2013.12.001","article-title":"Challenges and opportunities in the purification of recombinant tagged proteins","volume":"32","author":"Pina","year":"2014","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2026.05.019_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102799","article-title":"Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies","volume":"78","author":"Arvedson","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1006\/jmbi.2000.4265","article-title":"Stability engineering of antibody single-chain Fv fragments","volume":"305","author":"W\u00f6rn","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/v14122727","article-title":"Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy","volume":"14","author":"Wang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2026.05.019_bib41","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.ymthe.2022.04.011","article-title":"Pro-inflammatory concerns with lipid nanoparticles","volume":"30","author":"Seyed","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib42","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.019_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.omto.2023.02.004","article-title":"Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape","volume":"28","author":"Park","year":"2023","journal-title":"Mol. Therapy-Onolytics"},{"key":"10.1016\/j.ymthe.2026.05.019_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008733","article-title":"Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib45","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA Approval: Blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib46","first-page":"487","article-title":"FDA approves first DLL3 \u00d7 CD3 bispecific T-cell engager for lung cancer","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.019_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Bargou","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib48","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3389\/fimmu.2017.01181","article-title":"Targeting Malignant Brain Tumors with Antibodies","volume":"8","author":"Razpotnik","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib49","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib50","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-Cell Engaging Antibodies for Cancer Therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib51","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors","volume":"26","author":"Fuc\u00e1","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211008399","article-title":"Cell therapies in ovarian cancer","volume":"13","author":"Sarivalasis","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9378(90)91288-N","article-title":"Heterogeneity of antigen expression in advanced epithelial ovarIan cancer","volume":"162","author":"Berchuck","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ijc.2910430113","article-title":"Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells","volume":"43","author":"Boyer","year":"1989","journal-title":"Intl. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib55","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.05.019_bib57","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib58","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMAor GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.05.019_bib59","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1200\/JCO.2023.41.16_suppl.5571","article-title":"Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer","volume":"41","author":"Barakzai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib60","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.019_bib61","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1159\/000484109","article-title":"Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells","volume":"43","author":"Qu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ymthe.2026.05.019_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12185-020-03047-w","article-title":"Naoto Takahashi Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis","volume":"113","author":"Kobayashi","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib64","series-title":"Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting","article-title":"A phase 1 study of MGD007, a humanized gpA33 x CD3 DART\u00ae protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed\/refractory metastatic colorectal cancer","author":"Kim","year":"2018"},{"key":"10.1016\/j.ymthe.2026.05.019_bib65","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2026.05.019_bib66","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2026.05.019_bib67","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1158\/1078-0432.CCR-19-3275","article-title":"A novel GUCY2C-CD3 T-cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers","volume":"26","author":"Mathur","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib68","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/0008-5472.CAN-16-3431","article-title":"Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells","volume":"77","author":"Chang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.05.019_bib69","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1002\/cpz1.512","article-title":"Production of eukaryotic glycoproteins for structural and functional studies using Expi293F cells","volume":"2","author":"Greven","year":"2023","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.ymthe.2026.05.019_bib70","article-title":"Protein complex prediction with AlphaFold-Multimer","author":"Evans","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2026.05.019_bib71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.05.019_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/jb.00089-24","article-title":"Involvement of ArlI, ArlJ, and CirA in archaeal type IV pilin-mediated motility regulation","volume":"206","author":"Chatterjee","year":"2024","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ymthe.2026.05.019_bib73","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.3390\/cancers14204974","article-title":"Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability","volume":"14","author":"Borelli","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626004065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:45:44Z","timestamp":1785962744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626004065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626004065"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient in vivo assembly of DNA encoded polyvalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}